Anthracycline-induced cardiotoxicity — are we about to clear this hurdle?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anthracycline-induced cardiotoxicity — are we about to clear this hurdle?
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CANCER
Volume 185, Issue -, Pages 94-104
Publisher
Elsevier BV
Online
2023-02-25
DOI
10.1016/j.ejca.2023.02.019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010
- (2023) Carolyn M. Larsen et al. JAMA Network Open
- Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
- (2022) Xin-Ru Li et al. Journal of Ovarian Research
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
- (2022) Alexander R Lyon et al. EUROPEAN HEART JOURNAL
- Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
- (2022) Carmelita Abrahams et al. Lipids in Health and Disease
- Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer
- (2021) Sonu S. Varghese et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system—from molecular mechanisms to therapeutic applications
- (2020) Paweł Sobczuk et al. HEART FAILURE REVIEWS
- Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas
- (2020) William D. Tap et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The epigenetics changes associated with anthracyclines induced cardiotoxicity
- (2020) Marwa Tantawy et al. CTS-Clinical and Translational Science
- The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association ( HFA ), the European Association of Cardiovascular Imaging ( EACVI ) and the Cardio‐Oncology Council of the European Society of Cardiology ( ESC )
- (2020) Jelena Čelutkienė et al. EUROPEAN JOURNAL OF HEART FAILURE
- High cumulative doxorubicin dose for advanced soft tissue sarcoma
- (2020) Zhichao Tian et al. BMC CANCER
- Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
- (2019) Lee D Cranmer OncoTargets and Therapy
- A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma
- (2019) Brian A. Van Tine et al. Cancer Medicine
- Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis
- (2019) Lars Michel et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients
- (2018) Kelly Liesse et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients
- (2016) Markus K. Schuler et al. BMC CANCER
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model
- (2016) Nicole E. Frank et al. INVESTIGATIONAL NEW DRUGS
- Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404
- (2016) Barbara L. Asselin et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study
- (2015) Alex Rabinovich et al. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
- (2015) D. Cardinale et al. CIRCULATION
- First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma
- (2015) Sant P. Chawla et al. JAMA Oncology
- Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
- (2013) Marzia Lotrionte et al. AMERICAN JOURNAL OF CARDIOLOGY
- Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer
- (2013) Carlo Palmieri et al. Clinical Breast Cancer
- Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary?
- (2013) Sarah E. Gill et al. GYNECOLOGIC ONCOLOGY
- Identification of the molecular basis of doxorubicin-induced cardiotoxicity
- (2012) Sui Zhang et al. NATURE MEDICINE
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
- (2010) Lesley A Smith et al. BMC CANCER
- Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2010) Thomas Eschenhagen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis
- (2009) Anastasia Constantinidou et al. EUROPEAN JOURNAL OF CANCER
- Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
- (2008) D. Ravel et al. CLINICAL CANCER RESEARCH
- American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
- (2008) Martee L. Hensley et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started